CD19 t-haNK

CD19 t-haNK is a cell therapy whose type is not stated developed by ImmunityBio. Its target is CD19 (the sponsor names CD19). The sponsor states: CD19-targeted natural killer (haNK) cell therapy intended to bind CD19 on malignant B cells and drive immune-mediated cell death; studied in combination with the IL-15 superagonist N-803 (nogapendekin alfa inbakicept) and rituximab. ClinicalTrials.gov describes the intervention as: N-803 Subcutaneous (SQ): N-803 is a novel IL-15 superagonist immunotherapy administered subcutaneously. It is designed to enhance the proliferation and activation of natural killer (NK) cells and CD8+ T cells without stimulating regulatory. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma. The largest, NCT07125872, plans to enrol 20 participants with primary completion expected 2027-05-25. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.